Precision Medicine Is Revolutionizing Cancer Care.
Where classical medicine relied on symptoms, precision medicine uses genomics data to diagnose disease, and target therapies to the unique characteristics of each patient’s tumor. Liquid biopsies allow us to analyze tumor DNA directly from a blood sample, enabling early cancer detection and patient monitoring that are faster, less invasive, and scalable.
However, this is only half the story. Patients with the same tumor mutations can respond very differently to the same treatment. Many do not respond at all, even when therapies are chosen based on precise tumor data. The immune system is key to our health and essential for both cancer surveillance and treatment. Dynamic interaction of the immune response to the tumor, and to therapeutic intervention determines patient outcomes. But this has been difficult to measure at scale by existing methods, posing a significant limitation for patients, and presenting a substantial barrier to pharmaceutical innovation, making drug development unpredictable, slower, and more expensive than it needs to be.
Discover The Power Of Immune Intelligence. At Scale.
To deliver on the promise of precision medicine in oncology, we need to focus not only on the tumor but also on the immune system. To this end Novigenix has developed an ISO-13485 certified liquid biopsy (LBx) platform LITOSeek™ (Liquid ImmunoTranscriptOmics) utilizing whole-blood stabilized RNA that can be readily deployed in clinical trials and routine medical practice. Integrating NGS and AI, LITOSeek™ has been designed to comprehensively characterize the dynamic immune processes triggered by onset of cancer and therapeutic intervention.
LITOSeek™ excels in discovering robust immune biomarkers and developing predictive models for precise and early assessment of clinical response. The platform offers next generation biomarker solutions for clinical development and precision oncology, providing visibility into mechanisms of response and resistance, and offering cohort and subpopulation analysis.
Delivering data for better care across the patient journey
Precise and Predictive Data
LITOseek is the first ISO13485 certified immune liquid biopsy platform based on immuno-transcriptomics. It measures the gene activity of all the millions of immune cells in blood, providing a comprehensive view of the immune response. We use advanced AI to integrate this immune data with tumor DNA and clinical meta data for early detection of cancer, mechanism of action and resistance to therapeutic intervention, prediction of therapy response, and identifying toxicity biomarkers.
Innovative profiling
New advances in identifying biomarkers to understand the highly dynamic interplay between the immune system and cancer will dramatically improve our understanding of heterogeneity of patient response to therapeutic intervention, and catalyse the conversion of cancer into a manageable chronic disease.
The immune system is crucial for the patient`s response to cancer as well as to different therapeutic modalities, and it is itself has been the target of revolutionary new immunotherapy of cancer over the past decade. By understanding the immune response profile, we can significantly enhance efficient development of effective therapies and ultimately improve patients´ experience and the success of their therapeutic journey.
How we do it
